(Q37770597)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

review article

1 reference

title

An anticancer strategic dilemma: to kill or to contain. The choice of the pharmaceutical industry in 2009 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Bernard Uzzan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

Fundamental and Clinical Pharmacology

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

283-295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20608993%20AND%20SRC:MED&resulttype=core&format=json

Resistance to chemotherapy: new treatments and novel insights into an old problem

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Role of novel targeted therapies in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Targeted cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Rethinking "cancer as a dynamic developmental disorder" a quarter century later

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Theories of carcinogenesis: an emerging perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Models, mechanisms and clinical evidence for cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Cancer dormancy: opportunities for new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Apoptosis: target for novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Mitochondria as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Immunotherapy: target the stroma to hit the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Gene therapy approaches for the selective killing of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

From bench to bedside for gene-directed enzyme prodrug therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Targeted drugs for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Tumor stroma and regulation of cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Cancer: the matrix is now in control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Migratory neighbors and distant invaders: tumor-associated niche cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Tumor cells caught in the act of invading: their strategy for enhanced cell motility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Emerging multipotent aspects of hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

New pharmacological strategies against metastatic spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Network pharmacology: the next paradigm in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

The dilemma of anticancer therapy: tumor-specific versus immune effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00849.X